HILS could be a biotech rocket 🚀

*Sponsored by Lifewater Media. Please see disclosures below.

Good morning, Boardroom!

With all eyes firmly fixed on First Republic (FRC) and Big Tech this week…

(Not to mention all the media chatter surrounding Tucker Carlson and Bud Light)...

You probably overlooked this biotech gem — 

While the overall tech sector is roaring out of the gate with killer earnings, this little-known biotech firm which had their IPO last year at $4.00  — is set to carve out its stake.  

After months of choppy, sideways action…

It’s refreshing to come across a stock like this —

At first glance, HILS captured my attention as the sort of rare “nano-cap” gem that I like to get my hands on…

And after fully digging into the company…

I’m pleased to report that I was exactly right.

It’s got everything —

From market positioning… to the technicals… to the board and their roadmap…

This is one of those hidden stocks that you should have on your radar, immediately.

So without any further ado, let’s dig in and see what makes this stock so special.

First off, we’ve got:

1) Niche Market Domination

HILS is filling a CRITICAL void in the biotech market

Right now, oncology – the study and treatment of cancers – is a $283.5 BILLION market… one that’s expected to hit $581 BILLION in revenue by 2028…(1)

That’s not surprising when you consider that a cure for cancer would be the supreme medical miracle…

And the simple fact is:

HILS is doing its part to make that possible. 

Now, I’m no doctor, so I’m not going to get too deep into the specifics here…

(Here’s the rundown from actual medical experts) 

But essentially what these folks are doing is developing a viable alternative to traditional chemotherapy.

Let me put that into perspective for you.

HILS is spearheading the type of radical shift that’s capable of completely redefining the industry —

They’re working to do for medicine what Apple did for telecommunications… and we all know how that went.

Or think about tiny Illumina, Inc (ILMN) which rewarded shareholders with an incredible breakout from less than $1 to well over $500 per share in a matter of years as they developed their cancer-detection technology?

HILS’ therapeutics target solid tumors (which make up 90% of all cancer cases, and are notoriously difficult to treat) while reducing the likelihood of the nasty side effects.

The value in that simply cannot be understated.

If you’ve never witnessed a loved one undergoing chemotherapy — myself and many of my colleagues can attest —

It’s not a pretty picture.

It’s been accurately described as a treatment that kills the cancer slightly faster than it kills you… and that’s the best case scenario.

Rather than blasting folks with heavy doses of radiation and chemicals, HILS has developed what they call a “Quatramer.”

It’s a seek-and-destroy mechanism that delivers cancer-treating drugs directly to the tumor.

We’re talking about a technology with the potential to bring us much closer to a true cancer cure…

You can click this link here to see exactly how it works.

2) Sound Technicals & Insider Confidence

Confident insider holdings, low market cap, and a history of parabolic jumps are showing hot and heavy upside potential

As of this writing, HILS is sitting on a market cap of just $9.51 million, making it a true “nano-cap” company.

Meaning that even relatively small upticks in demand have the potential to send it soaring.

As an added bonus, the upside potential is magnified by the fact that so much of the company is privately held.

Right now company insiders are holding about 57% of shares (2), demonstrating high levels of confidence —

Which is a SHINING endorsement coming from a board that’s stacked with executives from biotech titans like DuPont, Merck, and even the founder and chairman of the Global Cancer Research Institute.

We’re looking at an all-star roster leading this project, and all it takes is a quick look at their balance sheet to see why they’re not hesitating to eat their own cooking:

Their debt-to-asset ratio is very low, indicating that today’s price of $0.71 is looking like a rock-solid springboard…

And with only 3.56M shares available to the public, this low-float stock has the potential for dramatic upswings…

Such a small liquidity pool has allowed relatively small bouts of buying pressure to send the stock skyrocketing by as much as 661% in less than two months.

That wasn’t ancient history, either —

It was happening just a few months ago:

And that’s far from the only time it’s gone parabolic:

We’re looking at a stock that seems to routinely jump by 60%... 70%... even 189% in just a few days…

While we can’t ever depend on the past to repeat itself, I’m anxiously anticipating that HILS will soon make one of the fast-charging moves higher that it has shown us over the past few months.

Which brings me to the MOST important factor I’m looking for in a short-term idea…

3) HUGE Forward Momentum

HILS proved itself in an early compassionate-use study in Germany, where the active ingredient in its premier drug showed efficacy on difficult-to-treat cancers including triple-negative breast cancer and epithelial carcinomas.

And now…

HILS is courting the FDA as early as June to authorize human drug trials.

I don’t think I need to tell you how massive this kind of news is for a biotech company.

This is the biotech equivalent of Hillstream BioPharma getting called up from the minors to pitch for the New York Yankees.

We’ve seen the headlines time and time again (3):

Like when AstraZeneca launched their clinical trials for a COVID vaccine — 

Investors who jumped in before the trial went live were capable of snatching up a 55% gain – in just three months.

They say history doesn’t always repeat itself, but it often rhymes…

And given the fact we’ve witnessed this same story play out like clockwork over the years…

Receiving the trial authorization is just the tip of the iceberg.

Once those trials are in motion, a steady stream of successful drug trials is capable of sending this stock into overdrive, potentially eclipsing even the 661% gain we saw earlier this year. 

Frankly, I could go on about this stock all day — 

We’ve got: 

• Niche market dominance ✔

• Sound technicals ✔

• A history of lightning-fast profits ✔

• Strong insider holdings (over 50%!) ✔

• And a MAJOR industry milestone just around the corner ✔

I mean, a stock with even a few of these factors is always worth taking a look…

But this stock is ticking every box, and all for less than a cup of coffee! 

Ultimately making HILS the type of rare gem that’s capable of delivering massive gains, even in a choppy market like the one we’ve been sitting through for the last few months.

Meaning it would be downright irresponsible of you, as a trader, to gloss over Hillstream BioPharma (NASDAQ: HILS) without at least clicking here to get the full rundown on the company right now.

I hope you love this stock as much as I do, but I always want to encourage you to do your own research and make sure that you are comfortable with the risks, and also the potential upside with this explosive idea. A great place to start is by visiting the company’s website.

Have a great day of trading, and I will be back soon with further updates.

To your success,

*Please see disclosures below